Stoke Therapeutics (STU:0GT) Additional Paid-In Capital : €523.08 Mil(As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Additional Paid-In Capital?

Stoke Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 (€513.51 Mil) to Dec. 2023 (€514.83 Mil) and increased from Dec. 2023 (€514.83 Mil) to Mar. 2024 (€523.08 Mil).

Stoke Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€366.41 Mil) to Dec. 2022 (€456.11 Mil) and increased from Dec. 2022 (€456.11 Mil) to Dec. 2023 (€514.83 Mil).

Stoke Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Stoke Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Additional Paid-In Capital Chart

Stoke Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

254.21

325.80

366.41

456.11

514.83

Stoke Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															498.86	499.27	513.51	514.83	523.08

Stoke Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Stoke Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Stoke Therapeutics (STU:0GT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (STU:0GT) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

STOK:USA

Address

45 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.stoketherapeutics.com

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.

Stoke Therapeutics (STU:0GT) Headlines

No Headlines